Previous reports show that in Bcr-Abl (Philadelphia) t(9;22) chromosome translocated leukemia, overexpression of the Bcr oligomerization domain or the mimicking peptide therapy aimed at oligomer dissociation of the Bcr-Abl protein demonstrated distinct anti-cancer activities in leukemia cell lines and some tumors resistant against Abl kinase inhibitors (18, 21–25). Here, BCR is linked to leukemia.